Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Jan 13, 2016Il sistema monouso per la rimozione dei calcoli elimina la necessità di manutenzione,“reprocessing” e sterilizzazioneBoston Scientific Corporation (NYSE: BSX) ha annunciato oggi l’immissione in commercio negli Stati Uniti e in Europa dell’ureteroscopio digitale flessibile monouso LithoVue™ per le procedure...
Jan 12, 2016Single-Use System for stone removal eliminates maintenance, reprocessing and sterilizationBoston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVueTM Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to...
- Jan 12, 2016
Einweg-System zur Steinentfernung kommt ohne Wartung, Wiederaufbereitung und Sterilisierung aus Boston Scientific Corporation (NYSE: BSX) hat heute die US-amerikanische und europäische...
-
Dec 11, 2015
Final results evaluating the Boston Scientific Corporation (NYSE: BSX) Precision Spectra™ Spinal Cord Stimulator (SCS) System demonstrate that the device provides more than 70 percent greater...
-
Nov 20, 2015In Europa sono stati eseguiti i primi impianti, che segnano l’inizio di una limitata immissione in commercio
Boston Scientific (NYSE: BSX) oggi ha annunciato che in seguito all’approvazione del marchio CE, in Europa sono stati eseguiti i primi impianti del dispositivo per la chiusura dell’auricola...
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...
-
Nov 19, 2015Erste Implantationen nach begrenzter Markteinführung in Europa.
Boston Scientific Corporation (NYSE: BSX) hat heute bekanntgegeben, dass die ersten Implantationen des WATCHMAN FLX™, der neuesten Generation der WATCHMAN-Implantate zum Verschluss des linken...
-
Nov 19, 2015Comienza la comercialización con los primeros implantes en Europa.
Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy la realización de los primeros implantes en Europa del dispositivo WATCHMAN FLX™ , de última generación, para el cierre de la...
-
Nov 9, 2015Topline data confirming peri-procedural safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ Left Atrial Appendage (LAA) Closure device was presented in an oral session during the American Heart Association (AHA) Scientific Sessions.
This is the first study to collect real-world WATCHMAN LAA Closure Device experience outside of selected populations in randomized trials. Results from the prospective, multi-centre EWOLUTION...
-
Sep 29, 2015Sesión interactiva sobre asma grave. Contaremos con los principales expertos europeos en asma y podrás escuchar el testimonio de un paciente al que le cambió la vida
28 de Septiembre, 2015, 18:30 – 20:00 Wyndham Apollo Hotel Amsterdam (a 15 minutos de la sede del Congreso ERS) Agenda 18:30 Bienvenida y presentaciones Sue Mayor, Moderador 18:40 Descubriendo...
-
Sep 29, 2015Tanto el trabajo como la vida social y familiar se ven afectados por el asma grave; muchos pacientes refieren sentir ansiedad, depresión y aislamiento.
Boston Scientific ha revelado hoy los resultados de una encuesta exhaustiva, que muestra la verdadera carga y las dificultades diarias a las que se enfrentan las personas con asma en Europa....
-
Sep 28, 2015A media briefing with a difference: join us for this interactive session on severe asthma. Hear from Europe’s leading experts in asthma and visit our information stations to bring the story to life.
September 28, 2015, 18:30 – 20:00 Wyndham Apollo Hotel Amsterdam (15 minutes from the ERS Congress Venue, the Amsterdam RAI Exhibition and Convention Centre) Agenda 18:30 Welcome and scene...
-
Sep 28, 2015Work, social and family life all affected by severe asthma, many people report feelings of anxiety, depression and isolation as well
Boston Scientific today revealed results of a comprehensive survey which shows the true burden of severe asthma and the daily challenges faced by people with asthma in Europe. Uncovering Asthma, a...
-
Sep 28, 2015MAJESTIC Trial Data Support Strong Safety Profile with Low Target Lesion Revascularization Rate
New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System reflect a primary patency rate1 of more...
-
Sep 28, 2015Schweres Asthma beeinträchtigt Arbeits-, Sozial- und Familienleben, viele Patienten berichten von Angstgefühlen, Depressionen und Isolation.
Boston Scientific hat heute die Ergebnisse einer umfassenden Umfrage zum tatsächlichen Ausmaß der Belastung durch schweres Asthma und den täglichen Herausforderungen von Asthma-Patienten in...
-
Sep 28, 2015Un incontro stampa che fa la differenza: ci auguriamo di averla nostro ospite alla sessione interattiva sull’asma grave, cui daranno il loro contributo i massimi esperti europei.
Lunedì 28 Settembre 2015 ore 18:30 – 20:00 Wyndham Apollo Hotel Amsterdam (a 15 minuti dalla sede del Congresso, dalla Amsterdam RAI Exhibition e dal Convention Centre) Agenda 18:30 Benvenuto...
-
Sep 28, 2015La vita professionale, sociale e familiare è condizionata dall’asma grave; molti pazienti riferiscono anche sensazioni di ansia, depressione e isolamento
Boston Scientific ha presentato oggi i risultati di un sondaggio su ampia scala che mostra il vero peso dell’asma grave e le difficoltà quotidiane affrontate dai pazienti affetti da asma in...
-
Sep 26, 2015
Results from clinical trials evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System continue to show this advanced transcatheter aortic valve implantation (TAVI) therapy delivers...
-
Sep 10, 2015System includes first directional lead with current steering and expanded programming flexibility
Boston Scientific (NYSE: BSX) has received CE Mark for the Vercise™ Primary Cell (PC) Deep Brain Stimulation (DBS) System. The Vercise PC System is intended to provide precise neural targeting...
-
Sep 9, 2015I benefici comportati dalla termoplastica bronchiale perdurano per anni, anziché per ore, diversamente da quanto accade col solo trattamento farmacologico.
Una tecnologia rivoluzionaria di Boston Scientific per il trattamento dell'asma grave si è dimostrata sicura ed efficace nell'arco di almeno cinque anni, secondo i dati pubblicati online da...
-
Aug 31, 2015
Boston Scientific welcomes the updated ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death announced during ESC Congress 2015, the...
-
Aug 31, 2015
Boston Scientific accoglie l’aggiornamento delle linee guida ESC per la gestione dei pazienti affetti da aritmie ventricolari e per la prevenzione della morte cardiaca improvvisa annunciato...
-
Aug 31, 2015
Boston Scientific begrüßt die aktualisierten ESC-Leitlinien für die Behandlung von Patienten mit ventrikulären Arrhythmien und zur Prävention des plötzlichen Herztodes. Diese wurden während...
-
Aug 31, 2015
Boston Scientific da la bienvenida a la actualización de las directrices de la ESC para tratar a pacientes con arritmias ventriculares y para prevenir la muerte súbita cardíaca, anunciadas...
-
Aug 24, 2015
Boston Scientific Corporation (NYSE: BSX) has received CE Mark on magnetic resonance imaging (MRI) conditional labeling for the current family of EL (Extended Longevity) and MINI implantable...
-
Aug 24, 2015L’aggiornamento della documentazione consente la compatibilità retroattiva con le scansioni MRI per i sistemi ICD e CRT-D a più lunga durata del settore
Boston Scientific Corporation (NYSE: BSX) ha ricevuto il marchio CE per la compatibilità con la risonanza magnetica per immagini (MRI) per le attuali famiglie di sistemi di defibrillatori...
-
Aug 24, 2015Die aktualisierte Indikation gewährleistet eine rückwirkende MRT-Kompatibilität der seit langem etablierten ICD- und CRT-D-Systeme
Die Boston Scientific Corporation (NYSE: BSX) hat das CE-Zeichnen für die MRT-Tauglichkeit der aktuellen implantierbaren EL- und MINI-Kardioverter-Defibrillatoren (ICD) sowie für die...
-
Aug 24, 2015La denominación actualizada permite la retrocompatibilidad con las pruebas de RM de los sistemas de DCI y CRT-D más duraderos del sector
Boston Scientific Corporation (NYSE: BSX) ha recibido el marcado CE para su familia actual de desfibriladores cardioversores implantables (DCI) de larga duración (EL) y MINI, y del desfibrilador...
-
Aug 4, 2015
Boston Scientific Corporation (NYSE: BSX) has closed on the previously announced agreement with Endo International plc (NASDAQ: ENDP) (TSX: ENL) to purchase the American Medical Systems (AMS)...
-
Aug 4, 2015
Boston Scientific Corporation (NYSE: BSX) ha cerrado el acuerdo, previamente anunciado, con Endo International plc (NASDAQ: ENDP) (TSX: ENL) para la adquisición del negocio de andrología y salud...
-
Jul 22, 2015
First Guidewire Designed Specifically for TAVI/R Now Sized for Smaller Ventricles Boston Scientific (NYSE: BSX) announces CE Mark and FDA clearance for the Safari2™ Pre-Shaped Guidewire, a new...
-
Jun 23, 2015The new generation of subcutaneous defibrillators selected as most innovative in the field of cardiac electrophysiology.
MILAN, Italy, June 23, 2014 – Attendees of EHRA EUROPACE-CARDIOSTIM 2015, a global medical conference held recently in Milan, Italy, have selected the EMBLEM™ S-ICD System as the most...
-
Jun 23, 2015
Die Teilnehmer der EHRA EUROPACE-CARDIOSTIM 2015, einer globalen Konferenz, die kürzlich in Mailand stattfand, haben das EMBLEM™-S-ICD-System zum innovativsten Produkt zur Verbesserung der...
-
Jun 22, 2015
Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for...
-
Jun 12, 2015Boston Scientific è lieta di invitarla alla presentazione stampa del nuovo sistema di protezione da morte cardiaca improvvisa “EMBLEM™” – defibrillatore impiantabile sottocutaneo (S-ICD)
SEGNI LA DATA IN AGENDA: 23 GIUGNO 2015 Milano Enterprise Hotel Corso Sempione, 91-93 20149 Milano, Italia Le presenteremo una esclusiva tecnologia salvavita. Il defibrillatore impiantabile...
-
Jun 10, 2015Please join us for a Boston Scientific press event. Protection from sudden cardiac death, just under the skin: the EMBLEM™ Subcutaneous ICD System
SAVE THE DATE: June 23, 2015. Milan, Italy. Enterprise Hotel Corso Sempione, 91-93 20149 Milan, Italy We would like to invite you to our press event on June 23, 2015 dedicated to an innovative,...
-
Jun 10, 2015Einladung zur Presseveranstaltung von Boston Scientific. Schutz vor plötzlichem Herzstillstand, direkt unter der Haut: das EMBLEM™ Subkutane-ICD System.
SAVE THE DATE: 23. Juni 2015. Mailand, Italien. Enterprise Hotel Corso Sempiore, 91-03 20149 Mailand, Italien Wir möchten Sie herzlich zu unserer Presseveranstaltung am 23. Juni 2015 rund um das...
-
Jun 10, 2015
¡RESERVA LA FECHA!: JUNIO 23, 2015. Milán, Italia. Enterprise Hotel Corso Sempione, 91-93 20149 Milán, Italia Es un placer invitarte al evento de prensa que tendrá lugar el próximo 23 de...
-
Jun 5, 2015El dispositivo de 16 contactos y batería desechable de alta capacidad más pequeña del mundo expande la oferta del sistema de estimulación de la médula espinal
Boston Scientific anuncia la comercialización del sistema Precision Novi™ para la estimulación de la médula espinal (EME) en la Sociedad Internacional de Neuromodulación en Montreal,...
-
Jun 4, 2015
World’s Smallest 16-Contact High-Capacity Primary Cell Device Expands Spinal Cord Stimulator System Offering Boston Scientific announces the European launch of the Precision Novi™ Spinal Cord...
-
Jun 4, 2015Das weltweit kleinste 16-Kontakt-Gerät mit Hochleistungs-Primärzelle erweitert das Angebot im Bereich der Rückenmarkstimulation
Im Rahmen des Kongresses der International Neuromodulation Society in Montreal, Kanada, kündigte Boston Scientific die europäische Markteinführung des Precision Novi™-Systems zur...
-
May 20, 2015
Compelling Results Presented at EuroPCR 2015 Add to Growing Body of Evidence Supporting Performance and Safety A new study evaluating the Boston Scientific (NYSE: BSX) Lotus™ Valve System...
-
May 19, 2015Additional Data from EVOLVE II Pivotal Trial Demonstrate Safety and Performance in Patients with Diabetes at One Year.
Boston Scientific (NYSE: BSX) reported positive, long-term data from the EVOLVE Trial of the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System, with no...
-
Apr 28, 2015MAJESTIC Trial Meets Performance Endpoint With Compelling Results
In an important clinical advancement in the treatment of peripheral artery disease (PAD), a key trial evaluating the Boston Scientific (NYSE: BSX) Eluvia™ Drug-Eluting Vascular Stent System met...
-
Apr 27, 2015
Boston Scientific Corporation (NYSE: BSX) announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and...
-
Apr 8, 2015
Boston Scientific Corporation (NYSE: BSX) hat die angekündigte Vereinbarung mit Endo International plc (NASDAQ: ENDP) (TSX: ENL) zur Übernahme der Bereiche Men’s Health und Prostate Health von...
-
Mar 19, 2015Innovative device offers first-line treatment for patients at risk of sudden cardiac arrest
Boston Scientific Corporation (NYSE: BSX) has received FDA and CE Mark approval of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System. The EMBLEM S-ICD System is a treatment...
-
Mar 13, 2015First-Of-Its-Kind Alternative to Long-Term Warfarin Therapy for Stroke Risk Reduction in Patients with Non-Valvular Atrial Fibrillation
Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the WATCHMAN Left Atrial Appendage Closure Device. The WATCHMAN Device offers a new...
-
Mar 13, 2015Un dispositivo innovador que ofrece una alternativa al tratamiento con warfarina a largo plazo para reducir el riesgo de ictus en los pacientes con fibrilación auricular no valvular.
Boston Scientific Corporation (NYSE: BSX) ha recibido la aprobación de su dispositivo WATCHMAN para el cierre de la orejuela auricular izquierda por parte de la Administración de alimentos y...
-
Oct 16, 2014The innovative devices allow pacemaker patients access to full body MRI scans in 1.5 Tesla and 3.0 Tesla systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the ACCOLADETM pacemaker family. When implanted with the company's INGEVITYTM leads, ACCOLADE pacemakers are the first...